Search results
Emcure Pharma IPO receives strong response, subscribed 67.86 times on third bidding day; Issue...
Livemint· 2 days agoAccording to data collected from the Bombay Stock Exchange (BSE) website, the Emcure Pharmaceuticals...
Mazgon Dock crosses Rs 1 trn mcap, Bansal Wire booked 5.72 times on day 2
Business Standard India· 3 days agoMotilal Oswal Nifty India Defence Index Fund collected Rs 1,676 crore during the new fund offer...
Lal Sweets looks to raise $40 mn from PE investors at $175 mn valuation
Livemint· 6 days agoThe company, which sells sweets, cookies and savouries, has received a term sheet from the private...
PE funds line up to take a bite of Belgian Waffle
The Economic Times· 2 days agoA lot is cooking in the food and beverages space. The Belgian Waffle is on the block with several large private equity buyout funds making a beeline to...
Shark Tank’s Namita Thapar to get Rs 128 crore from Emcure Pharma share sale
Financial Express· 5 days agoNamita Thapar, one of the judges of the famous TV show Shark Tank India will be partially offloading...
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of...
The Economic Times· 5 days agoThe initial public offering (IPO) of Emcure Pharmaceuticals will open for subscription on Wednesday,...
Shark Tank fame Namita Thapar likely to make around Rs 127 crore through Emcure Pharmaceuticals IPO...
The Times of India· 6 days agoNamita Thapar, a promoter group member of Emcure Pharmaceuticals and known for her appearance on...
Emcure Pharmaceuticals IPO subscription details on day 2 | India Infoline
India Infoline· 3 days agoEmcure Pharmaceuticals Ltd's IPO price band is set at ₹960-₹1,008 per share.
Namita Thapar-backed Emcure Pharma IPO opens for subscription. Should you bid?
The Economic Times· 5 days agoAhead of the issue opening, the company raised Rs 582 crore from anchor investors. Marquee investors...
Non-profit companies eye bigger fund raise through social exchange
Business Standard India· 2 days agoRecent filings aim to raise as much as 10x more than the norm